1. Abadie E, Ethgen D, Avouac B, Bouvenot G, Branco J, Bruyere O, Calvo G, Devogelaer JP, Dreiser RL, Herrero-Beaumont G, Kahan A, Kreutz G, Laslop A, Lemmel EM, Nuki G, Van De Putte L, Vanhaelst L, Reginster JY; Group for the Respect of Excellence and Ethics in Science. Recommendations for the use of new methods to assess the efficacy of disease-modifying drugs in the treatment of osteoarthritis. Osteoarthritis Cartilage. 2004;12:263–268.
2. Adams SS, Cobb R. Non-steroidal anti-inflammatory drugs. In: Progress in Medicinal Chemistry, 5, GP Ellis, GB West, eds. London: Butterworth, 1967, 59–133.
3. Allgayer H. Review article: mechanisms of action of mesalazine in preventing colorectal carcinoma in inflammatory bowel disease. Aliment Pharmacol Ther. 2003;18 Suppl 2:10–14.
4. Ambrosini MV, Mariucci G, Rambotti MG, Tantucci M, Covarelli C, De Angelis L, Del Soldato P. Ultrastructural investigations onprotective effects of NCX 4016 (nitroaspirin) on macrovascular endothelium in diabetic Wistar rats. J Submicrosc Cytol Pathol. 2005;37:205–213.
5. Bengmark S. Curcumin, an atoxic antioxidant and natural NFkappaB,cyclooxygenase-2, lipooxygenase, and inducible nitric oxide synthase inhibitor: a shield against acute and chronic diseases. JPEN J Parenter Enteral Nutr. 2006;30:45–51.